Entwicklung von Inhibitoren der unkonventionellen Sekretion von Fibroblast Growth Factor 2 - Erkenntnistransferprojekt

• Antragsteller: Professor Dr. Walter Nickel
• Fachliche Zuordnung: Biochemie
• Förderung: Förderung von 2018 bis 2023
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 389866291

• Erstellungsjahr: 2023

Zusammenfassung der Projektergebnisse

In this DFG technology transfer project, we put forward several goals, all aiming at the development of strategies to block the biological function of FGF2. While our most ambitious goal failed, the synthesis of C95-based FGF2 suicide inhibitors, we managed to develop a second generation of FGF2/Tec inhibitors with improved properties along with a deeper understanding of the structure activity relationships of these molecules. The scaffold of the FGF2/Tec inhibitors was now granted a patent and is offered to licensing partners. We further developed two cell-based assays, one of which is published and granted a patent. The second one will be subjected to a patent application soon and has been used to screen for potential FGF2 inhibitors, using the macrocycle library of our partner, Cyclenium Pharma. The development of the FGF2 macrocycle inhibitors has great potential and will be a major focus of our research group in the future. Based on these achievements, we believe the project produced important results.

Projektbezogene Publikationen (Auswahl)

• A time‐resolved live cell imaging assay to identify small molecule inhibitors of FGF2 signaling. FEBS Letters, 593(16), 2162-2176.
  Ahmed, Mennatallah; Legrand, Cyril; Yagüe, Relimpio Ana; Beretta, Carlo A.; Muschko, Alina; Wegehingel, Sabine; Müller, Hans‐Michael; Sehr, Peter; Will, David W.; Lewis, Joe D. & Nickel, Walter